U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H11N8O4S3.Na
Molecular Weight 462.462
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFTEZOLE SODIUM

SMILES

[Na+].[H][C@]12SCC(CSC3=NN=CS3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C([O-])=O

InChI

InChIKey=UGUMHWUOXWFPFH-JHQAJZDGSA-M
InChI=1S/C13H12N8O4S3.Na/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13;/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25);/q;+1/p-1/t8-,11-;/m1./s1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H11N8O4S3
Molecular Weight 439.473
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description is created based on several sources, including http://aksci.com/item_detail.php?cat=H709 and http://www.ncbi.nlm.nih.gov/pubmed/994325

Ceftezole sodium is a cephalosporin antibiotic. Ceftezole was found to be a broad-spectrum antibiotic, active in vitro against many species of gram-positive and gram-negative bacteria except Pseudomonas aeruginosa, Serratia marcescens and Proteus vulgaris. Ceftezole sodium is used as an injectable or through an intravenous mode of delivery. The bactericidal activity of ceftezole results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). The PBPs are transpeptidases which are vital in peptidoglycan biosynthesis. Therefore, their inhibition prevents this vital cell wall component from being properly synthesized. Ceftezole has been shown to exhibit potent alpha-glucosidase inhibitory activity. In in vitro alpha-glucosidase assays, ceftezole was shown to be a reversible, non-competitive inhibitor of yeast alpha-glucosidase with a Ki value of 5.78 x 10(-7) M when the enzyme mixture was pretreated with ceftezole. Ceftezole is used for the treatment of susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, endocarditis. Surgical prophylaxis.

Originator

Curator's Comment: Ceftezole sodium injection is a first-generation cephalosporin, developed by the Japanese company Fujisawa

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
PubMed

PubMed

TitleDatePubMed
Ceftezole, a cephem antibiotic, is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity.
2007 Sep
Exploring Mn-doped ZnS quantum dots for the room-temperature phosphorescence detection of enoxacin in biological fluids.
2008 May 15
Relapsing peritonitis caused by Bordetella bronchiseptica in continuous ambulatory peritoneal dialysis patient: a case report.
2009 Jan
Patents

Sample Use Guides

IM 2-4 g/day in 2-3 divided doses.
Route of Administration: Intramuscular
In Vitro Use Guide
Susceptibilities of 48 clinical isolates of S. aureus to ceftezole showed a peak at 0.20 ug/ml and no resistant strain with an MIC of 3.13 ug/ml or above was observed.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:32:20 GMT 2023
Edited
by admin
on Fri Dec 15 18:32:20 GMT 2023
Record UNII
3NHZ4Y117H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFTEZOLE SODIUM
JAN   MART.   WHO-DD  
Common Name English
CEFTEZOLE SODIUM SALT
MI  
Common Name English
CEFTEZOLE SODIUM SALT [MI]
Common Name English
CEFTEZOLE SODIUM [JAN]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 8-OXO-7-((1H-TETRAZOL-1-YLACETYL)AMINO)-3-((1,3,4-THIADIAZOL-2-YLTHIO)METHYL)-, MONOSODIUM SALT, (6R-TRANS)-
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 8-OXO-7-((2-(1H-TETRAZOL-1-YL)ACETYL)AMINO)-3-((1,3,4-THIADIAZOL-2-YLTHIO)METHYL)-, SODIUM SALT (1:1), (6R,7R)-
Common Name English
SODIUM (7R)-7-(2-(1H-TETRAZOL-1-YL)ACETAMIDO)-3-(1,3,4-THIADIAZOL-2-YLTHIOMETHYL)-3-CEPHEM-4-CARBOXYLATE
Common Name English
Ceftezole sodium [WHO-DD]
Common Name English
CEFTEZOLE SODIUM [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
Code System Code Type Description
MERCK INDEX
m1061
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY Merck Index
CAS
41136-22-5
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048594
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
EVMPD
SUB01136MIG
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
PUBCHEM
23688977
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
FDA UNII
3NHZ4Y117H
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
SMS_ID
100000084684
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
MESH
C012811
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
NCI_THESAURUS
C98231
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
ChEMBL
CHEMBL1697829
Created by admin on Fri Dec 15 18:32:20 GMT 2023 , Edited by admin on Fri Dec 15 18:32:20 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY